Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Capital Expenditures: 2018-2024

Historic Capital Expenditures for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to $7.1 million.

  • Avidity Biosciences' Capital Expenditures fell 58.22% to $712,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year increase of 192.15%. This contributed to the annual value of $7.1 million for FY2024, which is 67.12% up from last year.
  • Per Avidity Biosciences' latest filing, its Capital Expenditures stood at $7.1 million for FY2024, which was up 67.12% from $4.2 million recorded in FY2023.
  • Avidity Biosciences' 5-year Capital Expenditures high stood at $7.1 million for FY2024, and its period low was $1.1 million during FY2020.
  • Its 3-year average for Capital Expenditures is $4.7 million, with a median of $4.2 million in 2023.
  • Per our database at Business Quant, Avidity Biosciences' Capital Expenditures spiked by 364.68% in 2020 and then fell by 24.52% in 2022.
  • Over the past 5 years, Avidity Biosciences' Capital Expenditures (Yearly) stood at $1.1 million in 2020, then skyrocketed by 242.49% to $3.7 million in 2021, then dropped by 24.52% to $2.8 million in 2022, then spiked by 49.77% to $4.2 million in 2023, then surged by 67.12% to $7.1 million in 2024.